Valsartan is used clinical for receptor antagonist of angiotensin AT1, has good effect to the different degree of hypertension patients who used other antihypertensive without efficacy , is a new generation of highly efficient antihypertensive .
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, valsartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium.
Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.
Valsartan is an angiotensin II receptor antagonistwith particularly high affinity for the type I (AT1) angiotensin receptor. By blocking the action of angiotensin, valsartan dilates blood vessels and reduces blood pressure. In the U.S., valsartan is indicated for treatment of high blood pressure, congestive heart failure (CHF), or post-myocardial infarction (MI) .
Tine mafekitori akawanda emhando yepamusoro nekubatana kwakadzama, ayo anogona kukupa zvigadzirwa zvemhando yepamusoro nemitengo yemakwikwi. Uye isu tinogonawo kupa zvidzikiso pakutenga kwakawanda. Uye isu tinobatirana nemakambani mazhinji ehunyanzvi ekutakura zvinhu, anogona kuendesa zvigadzirwa zvakachengeteka uye zvakanaka kumaoko ako. Nguva yekutumira inenge 3-20 mazuva mushure mekusimbiswa kwekubhadhara.
Item | Test Standard | Testing Result | |
Chitarisiko | Powder | Zvinoenderana | |
Color | Upfu chena | Zvinoenderana | |
Particle Size | 100% pass 80 mesh | Zvinoenderana | |
Oder | Characteristic | Zvinoenderana | |
Taste | Characteristic | Zvinoenderana | |
Kurasika paKuomesa | ≤5.0% | 2.20% | |
Residue on Ignition | ≤0.1% | 0.05% | |
Residual acetone | ≤0.1% | Zvinoenderana | |
Residual Ethanol | ≤0.5% | Zvinoenderana | |
Heave Mentals | ≤10ppm | Zvinoenderana | |
Na | ≤0.1% | <0.1% | |
Pb | ≤3 ppm | Zvinoenderana | |
Total Plate | <1000CFU/g | Zvinoenderana | |
Yeast & Mold | <100 CFU /g | Zvinoenderana | |
E. Coli | Negative | Zvinoenderana | |
Salmonella | Negative | Zvinoenderana | |
Conclusion: Conform with USP Standard |
1. Iwe uri fekitori kana kambani yekutengesa?
Isu tiri compnay inobatanidza indasitiri nekutengeserana, ichipa one-stop service.OEM inogona kugamuchirwa.
2. Unopa mienzaniso here? Ndeyemahara here kana kuti yakawedzerwa?
Masampuli emahara. Mari yekutakura yemuyesheni inoda kubhadharwa parutivi rwako.
3. Iwe une chero zvitupa zvine chekuita nekutonga kwemhando?
ISO 9001:2008 certification kuti ive nechokwadi chemhando.
4. Chii chandinofanira kupa kuti ndiwane quotation?
Pls inotizivisa nezverudzi rwechigadzirwa chaunoda, huwandu hwekuraira, kero uye zvakananga zvinodiwa.The quotation ichaitwa kuti utarise nguva yako.
5. Ndeipi nzira yekubhadhara yaunoda? Ndeapi mazwi anogamuchirwa?
Mitemo Yekutumira Inogamuchirwa: FOB, CFR, CIF, EXW;
Mari Yekubhadhara Yakagamuchirwa: USD;
Accepted Payment Type: T/T,Western Union; Paypal,BTC
Mutauro Unotaurwa:Chirungu.
Zvigadzirwa zvikamu